{"id":23587,"date":"2025-04-13T17:40:01","date_gmt":"2025-04-13T17:40:01","guid":{"rendered":"https:\/\/globalsourcechemicals.com\/?post_type=product&p=23587"},"modified":"2025-10-03T07:27:28","modified_gmt":"2025-10-03T07:27:28","slug":"2-3-fea-40-mg-120-mg-kulur","status":"publish","type":"product","link":"https:\/\/globalsourcechemicals.com\/is\/bud\/naestum-bannad\/2-3-fea-40-mg-120-mg-kulur\/","title":{"rendered":"2\/3-FEA 40 MG\/120 MG k\u00falur"},"content":{"rendered":"

2\/3-FEA 40 MG \/ 120 MG k\u00falur \u2013 V\u00edsindaleg v\u00f6rul\u00fdsing<\/span><\/span><\/strong><\/h3>\n

Almennar uppl\u00fdsingar<\/span><\/span><\/strong><\/h4>\n

2\/3-FEA (2-fl\u00faorethamfetam\u00edn\/3-fl\u00faorethamfetam\u00edn)<\/span><\/span><\/strong> \u00a0er\u00a0 <\/span><\/span>ranns\u00f3knarefni \u00far fl\u00faoramfetam\u00ednaflei\u00f0ufj\u00f6lskyldunni<\/span><\/span><\/strong> , me\u00f0 hugsanlega \u00f6rvandi og samkennandi eiginleika. \u00deessar k\u00falur innihalda\u00a0 <\/span><\/span>N\u00e1kv\u00e6mlega sk\u00f6mmtun \u00e1 samsetningu af 40 mg af 2-FEA og 120 mg af 3-FEA<\/span><\/span><\/strong> , f\u00ednstillt fyrir\u00a0 <\/span><\/span>forkl\u00edn\u00edskar ranns\u00f3knir<\/span><\/span><\/strong> \u00a0e\u00f0a lyfhrifamiklar milliverkanir.<\/span><\/span><\/p>\n

\n

Notkun og ranns\u00f3knarsvi\u00f0<\/span><\/span><\/strong><\/h3>\n

Vegna einstakrar tv\u00edskiptrar uppbyggingar sinnar er 2\/3-FEA rannsaka\u00f0 fyrir:<\/span><\/span><\/p>\n

    \n
  1. \n

    Ranns\u00f3knir \u00e1 taugabo\u00f0efnum<\/span><\/span><\/strong> \u00a0\u2013 \u00c1hrif \u00e1 losun d\u00f3pam\u00edns, noradrenal\u00edns og ser\u00f3t\u00f3n\u00edns.<\/span><\/span><\/p>\n<\/li>\n

  2. \n

    Atferlisfr\u00e6\u00f0ileg lyfjafr\u00e6\u00f0i<\/span><\/span><\/strong> \u00a0\u2013 \u00c1hrif \u00e1 hreyfivirkni og umbunarkerfi \u00ed d\u00fdral\u00edk\u00f6num.<\/span><\/span><\/p>\n<\/li>\n

  3. \n

    \u00d6rvandi \u00e1hrif<\/span><\/span><\/strong> \u00a0\u2013 Samanbur\u00f0arranns\u00f3knir vi\u00f0 hef\u00f0bundi\u00f0 amfetam\u00edn.<\/span><\/span><\/p>\n<\/li>\n

  4. \n

    Ranns\u00f3knir \u00e1 s\u00e6kni vi\u00f0taka<\/span><\/span><\/strong> \u00a0\u2013 Ranns\u00f3kn \u00e1 s\u00e9rt\u00e6kni fyrir m\u00f3n\u00f3am\u00ednflutningspr\u00f3tein.<\/span><\/span><\/p>\n<\/li>\n<\/ol>\n

    \u26a0\u00a0Ekki \u00e6tla\u00f0 til manneldis \u2013 Eing\u00f6ngu til notkunar in vitro og \u00e1 d\u00fdratilraunum.<\/span><\/span><\/strong><\/p>\n

    \n

    Skammtar og lyfjagj\u00f6f<\/span><\/span><\/strong><\/h3>\n

    Forkl\u00edn\u00edskar lei\u00f0beiningar:<\/span><\/span><\/strong><\/h4>\n
      \n
    • \n

      L\u00e1gt virkt svi\u00f0:<\/span><\/span><\/strong> \u00a00,5-2 mg\/kg (fyrir v\u00e6g \u00e1hrif)<\/span><\/span><\/p>\n<\/li>\n

    • \n

      Mi\u00f0lungs svi\u00f0:<\/span><\/span><\/strong> \u00a02-5 mg\/kg (sk\u00fdr \u00e1hrif \u00e1 heg\u00f0un)<\/span><\/span><\/p>\n<\/li>\n

    • \n

      H\u00e1tt svi\u00f0:<\/span><\/span><\/strong> \u00a05-10 mg\/kg (eing\u00f6ngu fyrir ranns\u00f3knir \u00e1 br\u00e1\u00f0um eitur\u00e1hrifum)<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

      Leysni:<\/span><\/span><\/strong><\/h4>\n
        \n
      • \n

        Fr\u00edleysanlegt \u00ed\u00a0 <\/span><\/span>l\u00edfe\u00f0lisfr\u00e6\u00f0ilegt saltvatn<\/span><\/span><\/strong> \u00a0(til innd\u00e6lingar)<\/span><\/span><\/p>\n<\/li>\n

      • \n

        L\u00e9ttleysanlegt \u00ed\u00a0 <\/span><\/span>DMSO<\/span><\/span><\/strong> \u00a0(fyrir ranns\u00f3knir \u00ed tilraunaglasi)<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

        Lyfjagj\u00f6f:<\/span><\/span><\/strong><\/h4>\n
          \n
        • \n

          Munnleg (d\u00fdral\u00edk\u00f6n)<\/span><\/span><\/p>\n<\/li>\n

        • \n

          \u00cd kvi\u00f0arholi (fyrir hra\u00f0ari fr\u00e1sog)<\/span><\/span><\/p>\n<\/li>\n

        • \n

          In vitro flutningspr\u00f3teinpr\u00f3fanir<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

          \n

          \u00d6ryggis\u00fe\u00e6ttir og \u00e1h\u00e6tta<\/span><\/span><\/strong><\/h3>\n

          Br\u00e1\u00f0 \u00e1h\u00e6tta:<\/span><\/span><\/strong><\/h4>\n
            \n
          • \n

            Hjarta- og \u00e6\u00f0akerfi\u00f0<\/span><\/span><\/strong> \u00a0(aukinn hjartsl\u00e1ttur\/bl\u00f3\u00f0\u00fer\u00fdstingur)<\/span><\/span><\/p>\n<\/li>\n

          • \n

            \u00a0St\u00f3r skammtur <\/span>ofhitnun<\/span><\/strong><\/span><\/p>\n<\/li>\n

          • \n

            Ser\u00f3t\u00f3n\u00edn heilkenni<\/span><\/span><\/strong> \u00a0\u00feegar \u00fea\u00f0 er nota\u00f0 \u00e1samt MAO-hemlum<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

            Langvinn \u00e1h\u00e6tta:<\/span><\/span><\/strong><\/h4>\n
              \n
            • \n

              Taugaeitur\u00e1hrif<\/span><\/span><\/strong> \u00a0(vi\u00f0 langt\u00edmanotkun \u00ed st\u00f3rum sk\u00f6mmtum)<\/span><\/span><\/p>\n<\/li>\n

            • \n

              D\u00f3pam\u00ednvirka t\u00e6mingu<\/span><\/span><\/strong><\/p>\n<\/li>\n

            • \n

              Heg\u00f0unarn\u00e6mi<\/span><\/span><\/strong><\/p>\n<\/li>\n<\/ul>\n

              \n

              Ranns\u00f3knarstofugreining og g\u00e6\u00f0aeftirlit<\/span><\/span><\/strong><\/h3>\n

              Greiningaruppl\u00fdsingar:<\/span><\/span><\/strong><\/h4>\n
                \n
              • \n

                Sta\u00f0festing \u00e1 HPLC-MS<\/span><\/span><\/strong> \u00a0af samsetningu<\/span><\/span><\/p>\n<\/li>\n

              • \n

                Hlutfall 1:3 (2-FEA:3-FEA)<\/span><\/span><\/strong> \u00a0me\u00f0 <5% dreifni<\/span><\/span><\/p>\n<\/li>\n

              • \n

                Engin greinanleg \u00eds\u00f3mer\u00edsk \u00f3hreinindi<\/span><\/span><\/strong><\/p>\n<\/li>\n

              • \n

                \u00d6rverufr\u00e6\u00f0ileg hreinleiki:<\/span><\/span><\/strong> \u00a0<100 CFU\/g<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

                St\u00f6\u00f0ugleikag\u00f6gn:<\/span><\/span><\/strong><\/h4>\n
                  \n
                • \n

                  Geymslu\u00feol:<\/span><\/span><\/strong> \u00a024 m\u00e1nu\u00f0ir vi\u00f0 4\u00b0C<\/span><\/span><\/p>\n<\/li>\n

                • \n

                  Lj\u00f3sn\u00e6mi:<\/span><\/span><\/strong> \u00a0Geymi\u00f0 \u00ed gulbr\u00fanum umb\u00fa\u00f0um<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

                  \n

                  R\u00e1\u00f0lag\u00f0ar ranns\u00f3knarreglur<\/span><\/span><\/strong><\/h3>\n
                    \n
                  1. \n

                    Ranns\u00f3knir \u00e1 \u00f6rskilun<\/span><\/span><\/strong><\/p>\n

                      \n
                    • \n

                      Raunt\u00edmaeftirlit me\u00f0 utanfrumud\u00f3pam\u00edni \u00ed kjarna accumbens<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n

                    • \n

                      Skilyrt sta\u00f0arval<\/span><\/span><\/strong><\/p>\n

                        \n
                      • \n

                        Mat \u00e1 hugsanlegum umbunum<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n

                      • \n

                        Ranns\u00f3knir \u00e1 hitast\u00fdringu<\/span><\/span><\/strong><\/p>\n

                          \n
                        • \n

                          \u00c1hrif \u00e1 l\u00edkamshita<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n

                        • \n

                          Rafl\u00edfe\u00f0lisfr\u00e6\u00f0i<\/span><\/span><\/strong><\/p>\n

                            \n
                          • \n

                            Greining \u00e1 skotmynstri d\u00f3pam\u00edns taugafrumna<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n

                            \n

                            Algengar spurningar<\/span><\/span><\/strong><\/h3>\n

                            Spurning 1: Hver er helsti munurinn \u00e1 2-FEA og 3-FEA?<\/span><\/span><\/strong>
                            \n A: 2-FEA s\u00fdnir meiri\u00a0 <\/span><\/span>d\u00f3pam\u00ednvirk s\u00e9rt\u00e6kni<\/span><\/span><\/strong> , en 3-FEA hefur sterkari\u00a0 <\/span><\/span>ser\u00f3t\u00f3n\u00ednvirk \u00e1hrif<\/span><\/span><\/strong> \u00a0.<\/span><\/span><\/p>\n

                            Spurning 2: Hvernig ber \u00feessi samsetning sig saman vi\u00f0 3-FMA?<\/span><\/span><\/strong>
                            \n A: 2\/3-FEA samsetningin hefur\u00a0 <\/span><\/span>v\u00e6gari \u00e1hrifapr\u00f3f\u00edll<\/span><\/span><\/strong> \u00a0me\u00f0 minni m\u00f6guleika \u00e1 taugaeitur\u00e1hrifum.<\/span><\/span><\/p>\n

                            Spurning 3: Er h\u00e6tta \u00e1 myndun \u00eds\u00f3mera?<\/span><\/span><\/strong>
                            \n A: Greiningarg\u00f6gn okkar s\u00fdna a\u00f0\u00a0 <\/span><\/span>engar \u00f3\u00e6skilegar \u00eds\u00f3merar<\/span><\/span><\/strong> \u00a0myndast \u00feegar \u00fe\u00e6r eru geymdar r\u00e9tt.<\/span><\/span><\/p>\n

                            \n

                            L\u00f6gleg athugasemd:<\/span><\/span><\/strong>
                            \n \u00deessi vara fellur undir\u00a0 <\/span><\/span>\u00d3p\u00eduml\u00f6gin<\/span><\/span><\/strong> \u00a0\u00ed Hollandi og er\u00a0 <\/span><\/span>eing\u00f6ngu \u00e6tla\u00f0 til l\u00f6glegra v\u00edsindaranns\u00f3kna<\/span><\/span><\/strong> \u00a0me\u00f0 nau\u00f0synlegum leyfum.<\/span><\/span><\/p>\n

                            Geymsluskilyr\u00f0i:<\/span><\/span><\/strong><\/p>\n

                              \n
                            • \n

                              Hitastig: 2-8\u00b0C<\/span><\/span><\/p>\n<\/li>\n

                            • \n

                              Vernda\u00f0 gegn raka og lj\u00f3si<\/span><\/span><\/p>\n<\/li>\n

                            • \n

                              Geymi\u00f0 fjarri matv\u00e6lum<\/span><\/span><\/p>\n<\/li>\n<\/ul>\n

                              ","protected":false},"excerpt":{"rendered":"

                              Skipt \u00fat fyrir Newphoria 2\/3-FEA k\u00falur >><\/span><\/span><\/span><\/span><\/strong><\/span><\/p>","protected":false},"featured_media":27753,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[322,333,324],"product_tag":[326],"class_list":{"0":"post-23587","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-bijna-verboden","7":"product_cat-gefluoreerden","8":"product_cat-pellets-for-pellet","9":"product_tag-nl","11":"first","12":"instock","13":"taxable","14":"shipping-taxable","15":"purchasable","16":"product-type-variable"},"_links":{"self":[{"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/product\/23587","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/comments?post=23587"}],"version-history":[{"count":5,"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/product\/23587\/revisions"}],"predecessor-version":[{"id":28068,"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/product\/23587\/revisions\/28068"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/media\/27753"}],"wp:attachment":[{"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/media?parent=23587"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/product_brand?post=23587"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/product_cat?post=23587"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/globalsourcechemicals.com\/is\/wp-json\/wp\/v2\/product_tag?post=23587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}